GNRH1 and endometrial cancer: Preoperative use of dienogest, progestin, GnRH agonists, or antagonists can keep the endometrium in the thin phase, enhancing surgical access and minimizing intraoperative bleeding. Relugolix theoretically has a role in endometrial cancer management due to its hormone-suppressing effects, but it is not commonly used due to limited clinical evidence and the preference for more established therapies like progestins, which act directly on endometrial cells to counteract estrogen’s effects rather than merely reducing hormone production [4].